Omeza Announces Appointment of Brad Scheckner as VP, Field Sales and Operations

Omeza, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today announced the appointment of Brad Scheckner as Vice President, Field Sales and Operations.

“Omeza’s rapid ascent from a start-up with a promising concept to a commercial-stage company with an FDA-approved product is a testament to our scientific acumen, robust clinical data, and sound operational infrastructure — one that we continue to build and grow with new talent,” said Cynthia Flowers, Chief Executive Officer of Omeza.

“We’re thrilled to have Brad at the helm of our field force to create a culture of empowerment that drives the team to surpass sales targets and generate substantial revenue. His proven success in building teams and launching products is critical as we realize the potential of Omeza’s suite of wound-care products.”

Brad Scheckner brings more than two decades of experience across biopharmaceutical, diagnostic, and medical device companies, including field sales and leadership positions at Genzyme, Sanofi, Crescendo Bioscience, Flexion Therapeutics, and Electromedical Products International. He possesses significant cross-functional expertise in strategic marketing, market and payer access, business analytics, and business development as well as extensive knowledge of target healthcare settings, from specialty practices and ambulatory surgical centers to Veterans Affairs hospitals and the Department of Defense.

Throughout his career, he has built and led multiple first-line management and sales teams, overseeing four product launches across various disease states. Additionally, Mr. Scheckner has served in multiple leadership roles in which he has liaised with marketing, business analytics, and employee engagement teams to develop a cohesive strategic approach that aligns the organization with sales in the pursuit of common goals and objectives.

Mr. Scheckner is a graduate of Florida State University, where he earned his degree in Business Management. He currently resides in Sarasota, Fla.

SourceOmeza

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.